Malignant Neoplasm of Nasopharynx Clinical Trial
Official title:
A Prospective, Randomized Controlled Open Research About the Impact of Nutritional Support on the Radiation Tolerance and Clinical Outcomes for Local Advanced Nasopharyngeal Carcinoma Patients
Verified date | November 2018 |
Source | Zhejiang Cancer Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The chemo-radiotherapy for the local advanced nasopharyngeal carcinoma patients will induce the mucosal ulcer and damage salivary glands. Consequently, it can disturb the nutrition conditions and clinical outcomes of patients. This research tries to evaluate the nutrition status at the baseline, before and after radiotherapy, during the follow-up by the body mass index, hematological indexes, immunological indexes, and nutrition questionnaires including PG-SGA and NRS 2002. Through the evaluation of two different nutritional interventions, the investigators aim to find an optimized assessment model and the best nutrition support patterns.
Status | Active, not recruiting |
Enrollment | 114 |
Est. completion date | October 2019 |
Est. primary completion date | November 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Histologically conformed Initial nasopharyngeal carcinoma 2. Patients can feed through the mouth. 3. ECOG (Eastern Cooperative Oncology Group) : 0-2. 4. No history of chemo-radiotherapy, immuno-therapy or biotherapy. 5. Normal hemodynamic indices before the recruitment (including white blood cell count>4.0×109/L, neutrophil count>1.5×109/L, platelet count >100×109/L, hemoglobin=90g/l, normal liver/kidney function). 6. Informed consent signed. Exclusion Criteria: 1. History of malignant tumors. 2. Any severe complications contraindicated chemotherapy or radiotherapy. 3. Medical history of central nervous system, cognitive or psychological diseases; 4. Pregnant or nursing women. 5. Patients with mental disease cannot complete the questionaire. 6. Patients refused the informed consent. |
Country | Name | City | State |
---|---|---|---|
China | Zhejiang Cancer Hospital | Hangzhou | Zhejiang |
China | Zhejiang Cancer Hosptial | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Zhejiang Cancer Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival | From the first treatment to the death of any causes | 5 years | |
Secondary | Progress free survival | From the first treatment to the progress of diseases | 5 years |